Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporin and steroids in renal transplantation

Clinical Transplantation

Volumn 17, Issue 6, 2003, Pages 511-517

  Pescovitz, Mark D ^a   Bumgardner, Ginny ^b   Gaston, Robert S ^c   Kirkman, Robert L ^d,g   Light, Susan ^e   Patel, Indravadan H ^e   Nieforth, Keith ^e   Vincenti, Flavio ^f  

^a INDIANA UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HOFFMANN LA ROCHE INC   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g PROTEIN DESIGN LABS INC   (United States)

Author keywords

Daclizumab; Mycophenolate mofetil; Pharmacokinetic; Renal transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; DRUG METABOLITE; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE; OKT 3; PLACEBO; PREDNISONE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADULT; AREA UNDER THE CURVE; ARTICLE; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; FEMALE; GRAFT SURVIVAL; HERPES; HUMAN; INCIDENCE; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; LABORATORY TEST; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MENINGITIS; PNEUMONIA; POSTOPERATIVE INFECTION; PREOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SEPSIS; SIDE EFFECT; SURVIVAL RATE; THRUSH;

ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOCORTICOIDS; GLUCURONATES; GLUCURONIDES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; KIDNEY TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; TIME FACTORS;

EID: 0345329426     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1399-0012.2003.00079.x     Document Type: Article

References (15)

1. Queen C, Schneider WP, Selick HE et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989: 86: 10029.
2. Vincenti F, Kirkman R, Light S et al. Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998: 338: 161.
3. Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999: 67: 110.
4. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995: 345: 1321.
5. Tricontinental Mycophenolate Mofetil Renal Transplant Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996: 61: 1029.
6. Sollinger HW for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995: 60: 225.
7. Carswell CI, Plosker GL, Wagsta A. Daclizumab - a review of its use in the management of organ transplantation. BioDrugs 2001: 15: 745.
8. Tsina I, Chu F, Hama K et al. Manual and automated (robotic) high-performance liquid chromatography methods for the determination of mycophenolic acid and its glucuronide conjugate in human plasma. J Chromatogr B Biomed Appl 1996: 675: 119.
9. Fayer BE, Soni PP, Binger MH, Mould DR, Satoh H. Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assay. J Immunol Methods 1995: 186: 47.
10. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications, 3rd edn. Philadelphia, PA: Lippincott, Williams & Wilkins, 1995: 207.
11. FDA Guidance for Industry: In Vivo Drug Metabolism/Drug Interaction Studies - Study Design, Data Analysis, and Recommendations for Dosing and Labeling. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), November 1999, Clin/Pharm.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976: 16: 31.
13. Kovarik JM, Pescovitz MD, Sollinger HW et al for the Simulect Phase IV Study Group. Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. Clin Transplant 2001: 15: 123.
14. Hengster P, Pescovitz MD, Hyatt D, Margreiter R. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group. Transplantation 1999: 68: 310.
15. Deierhoi MH, Hudson SL, Gaston RS. Clinical experience with a two dose regimen of daclizumab in cadaveric renal transplantation [abstract]. Transplantation 2000: 69: S260.